Mark T. Osterman - Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine

基本信息

浏览量：61

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 188 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Su1791 DURABILITY OF RESPONSE IN DELAYED RESPONDERS TO OZANIMOD IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGICS: 3-YEAR UPDATE FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Miguel D. Regueiro,Geert D'Haens,Raymond K. Cross,Lisa Malter,Peter M. Irving,Hsiuanlin Wu, Sonie Lama,Garrett Lawlor,Mark T. Osterman,Anjali Jain,Axel Dignass

Gastroenterologyno. 5 (2024): S-815

引用0浏览0引用

Long-term Efficacy of Ozanimod Up to 3 Years in Patient Response Subgroups Identified Using Group-Based Trajectory Modelling

S. W. Schreiber,B. G. Feagan,B. E. Sands,F. Rieder, J. Torres, Z. Liu,A. Jain,A. M. Poehler,H. Wu,M. T. Osterman,M. T. Abreu,P. S. Dulai

JOURNAL OF CROHNS & COLITIS（2024）

引用0浏览0引用

P637 Ozanimod Efficacy with or Without Concomitant Corticosteroids in 5-Asa–exposed, Advanced Therapy–naive, Immunomodulator-Naive Patients with Ulcerative Colitis: a Post Hoc Analysis of True North

S Horst, M Fischer, J A Kinnucan, J S Sauk, H Wu, A Jain, H A Ahmad,M T Osterman, M Rosen,B E Sands

Journal of Crohn's and Colitisno. Supplement_1 (2024)

引用0浏览0引用

DOP78 Efficacy of Ozanimod by Patient Response Trajectory Subgroups Identified Using Group-Based Trajectory Modelling: a Post Hoc Analysis of the Phase 3 True North Study

S W Schreiber,B G Feagan,B E Sands,F Rieder, J Torres, Z Liu,A Jain,A M Poehler,H Wu,M T Osterman,M T Abreu,P S Dulai

Journal of Crohn's and Colitis（2024）

引用0浏览0引用

6-Mercaptopurine and Azathioprine in Crohn's Disease

Mark T. Osterman,Gary R. Lichtenstein

Crohn's Diseasepp.157-175, (2024)

引用0浏览0引用

Ozanimod efficacy with or without concomitant corticosteroids in 5-ASA-exposed, advanced therapy-naive, immunomodulator-naive patients with ulcerative colitis: a post hoc analysis of True North

S. Horst, M. Fischer, J. A. Kinnucan, J. S. Sauk, H. Wu, A. Jain,H. A. Ahmad,M. T. Osterman, M. Rosen,B. E. Sands

JOURNAL OF CROHNS & COLITIS (2024): I1211-I1212

引用0浏览0引用

P789 Impact of Risk Factors for Janus Kinase Inhibitor Use Identified by the Pharmacovigilance Risk Assessment Committee on the Safety and Efficacy of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis

B. Siegmund,T. Kuehbacher,A. Armuzzi, A. Hart,B. Bressler,B. G. Feagan,H. Wu,H. A. Ahmad,M. T. Osterman,L. Charles,A. M. Poehler,A. Jain,S. Danese

JOURNAL OF CROHNS & COLITIS (2024): I1461-I1463

引用0浏览0引用

Impact of Recent Thiopurine Use on Ozanimod Safety in Patients with Ulcerative Colitis: a Post Hoc Analysis of the Phase 3 True North Study

R. Battat,R. Panaccione, A. Hart,T. Hisamatsu,H. A. Ahmad,M. T. Osterman,H. Wu,A. Jain, M. Rosen,B. Siegmund

JOURNAL OF CROHNS & COLITIS (2024): I1100-I1101

引用0浏览0引用

Efficacy of Ozanimod by Patient Response Trajectory Subgroups Identified Using Group-Based Trajectory Modelling: a Post Hoc Analysis of the Phase 3 True North Study

S. W. Schreiber,B. G. Feagan,B. E. Sands,F. Rieder, J. Torres, Z. Liu,A. Jain,A. M. Poehler,H. Wu,M. T. Osterman,M. T. Abreu,P. S. Dulai

JOURNAL OF CROHNS & COLITIS（2024）

引用0浏览0引用

Su1766 OZANIMOD IS MORE EFFECTIVE IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS WITH ENDOSCOPICALLY MODERATE VS SEVERE DISEASE REGARDLESS OF BASELINE PATIENT-REPORTED OUTCOMES OR PRIOR IMMUNOMODULATOR EXPOSURE

Jean Frederic Colombel,Stephen B. Hanauer,Andres Yarur,Triana Lobaton,Maia Kayal,Mark A. Samaan,Mark T. Osterman,Harris Ahmad,Hsiuanlin Wu,Anjali Jain,Toshifumi Hibi

GASTROENTEROLOGYno. 5 (2024): S803-S804

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn